Menu Search
Equities

Tianjin TEDA Biomedical Engineering Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8189:HKG.HS

Tianjin TEDA Biomedical Engineering Co Ltd

Actions
  • Price (HKD)0.32
  • Today's Change0.01 / 3.23%
  • Shares traded40.00k
  • 1 Year change-20.00%
  • Beta0.2790
Data delayed at least 15 minutes, as of Feb 16 2026 02:24 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tianjin TEDA Biomedical Engineering Co Ltd is a China-based company primarily engaged in the manufacture and sale of biological compound fertiliser products. The Company mainly operates its business through two segments. The Fertiliser Products segment is engaged in the manufacture and sale of biological compound fertiliser products, including active fertiliser, mixture with nitrogen, phosphorus and potassium with various formula, providing warehousing services and processing and licensing of the fertiliser products. The Elderly Care & Health Care Services segment is engaged in the provision of integrated elderly care and health care services, including the leasing of elderly equipment. The Company mainly conducts its business in the domestic market.

  • Revenue in HKD (TTM)452.89m
  • Net income in HKD-36.15m
  • Incorporated2000
  • Employees260.00
  • Location
    Tianjin TEDA Biomedical Engineering Co Ltd9F, Block A2 Tianda High-tech Park No.80The 4th AvenueTianjin Eco and Tech Dev AreaTIANJIN 300457ChinaCHN
  • Phone+86 2 259816900
  • Fax+86 2 259816909
  • Websitehttp://www.bioteda.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.